Eli Lilly and Company today announced that the National Medical Products Administration (NMPA) in China has approved Kisunlatm (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion) ...

Sleep is important for many things, but not getting enough on a regular basis can be the start of serious health problems ...